NanoViricides Reports FluCide Well-Tolerated in non-GLP Small Animal Tox Study

NanoViricides NNVC reports that its optimized injectable FluCide drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide. This study will provide guidance for the IND-enabling GLP safety and toxicology study. The Company previously had a pre-IND meeting with the U.S. FDA to discuss and receive guidance on the FluCide drug development pathway. This non-GLP safety and toxicology study was begun in late September at KARD Scientific in Massachusetts. Dr. Krishna Menon, VMD, PhD, CEO of KARD Scientific, advised the Company after the completion of this short study, that mice treated with the See full press release